CART%20Cell%20Therapy
Showing 1 - 25 of >10,000
Leukemia, Lymphoma, Cardiotoxicity Trial in Philadelphia
Completed
- Leukemia
- +4 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jan 19, 2023
Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy Trial (ultra-fraction radiotherapy)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- ultra-fraction radiotherapy
- (no location specified)
Aug 22, 2022
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
Ovarian Cancer Trial in Shanghai (anti- MESO CAR-T cells, Fludarabine, Cyclophosphamide)
Recruiting
- Ovarian Cancer
- anti- MESO CAR-T cells
- +2 more
-
Shanghai, Shanghai, ChinaShanghai 6th People's Hospital
Aug 9, 2021
Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, Selinexor-VRD)
Recruiting
- Multiple Myeloma
- anti-BCMA CAR-T
- Selinexor-VRD
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
May 12, 2023
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
Multiple Myeloma Trial in Philadelphia (BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART
Active, not recruiting
- Multiple Myeloma
- BCMA CART + huCART19
- +2 more
-
Philadelphia, PennsylvaniaUniv. of Pennsylvania
Jul 11, 2022
ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell
Recruiting
- Relapsed Non Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jun 7, 2021
SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy
Recruiting
- Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
- COVID-19 serology IgG
-
Detroit, MichiganHenry Ford Health System
Jul 19, 2022
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
CART Therapy Trial in Madrid
Completed
- CART Therapy
-
Madrid, SpainAngel Cedillo
May 26, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Leukemia, T Cell Trial in Beijing (CD7 CART)
Recruiting
- Leukemia, T Cell
- CD7 CART
-
Beijing, Hebei, ChinaHe bei Yan da Lu dao pei Hospital
May 24, 2022
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T)
Recruiting
- Plasma Cell Leukemia
- anti-BCMA CAR-T
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
May 13, 2023
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- CAR.CD30 T cells
-
Chapel Hill, North Carolina
- +2 more
Mar 16, 2022
Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)
Not yet recruiting
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
- Bone Marrow Aspiration
- +10 more
-
Los Angeles, CaliforniaMelanie Ayala Ceja
Jul 10, 2023
Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,
Recruiting
- Recurrent Neuroblastoma
- +3 more
- Cyclophosphamide
- +2 more
-
Palo Alto, California
- +3 more
Jan 25, 2023
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)
Unknown status
- Relapsed Non Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- CD19/22 CART
- Tislelizumab
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 30, 2021
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Multiple Myeloma Trial in Boston, Milwaukee (CART-ddBCMA)
Not yet recruiting
- Multiple Myeloma
- CART-ddBCMA
-
Boston, Massachusetts
- +1 more
Jul 7, 2022
Study for Patients Treat With WU-CART-007
Enrolling by invitation
- T-cell Acute Lymphoblastic Leukemia
- T-cell Lymphoblastic Lymphoma
- Genetic: WU-CART-007
-
Saint Louis, MissouriWashington University
Aug 18, 2022
Multiple Myeloma Trial in Philadelphia (CART-19 cells)
Terminated
- Multiple Myeloma
- CART-19 cells
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jan 4, 2023
Leukemia, Lymphoma Trial in Beijing (Anti-CD22-CAR-transduced T cells)
Unknown status
- Leukemia
- Lymphoma
- Anti-CD22-CAR-transduced T cells
-
Beijing, Beijing, ChinaFengtai District
Feb 6, 2021